



COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

Virginia Medicaid
Drug Utilization Review (DUR) Board

2pm

Thursday, November 20, 2014

DMAS Board Room 13th Floor

Agenda

1. Call to Order and Introductions – Randy Ferrance, MD, Chair
2. Minutes
 - a. Approval of Minutes from August 21, 2014 meeting
3. New Drugs
 - a. Cerdelga[™] (eliglustat)
 - b. Jardiance[®] (empagliflozin)
 - c. Kerydin[™] (tavaborole)
 - d. Northera[™] (droxidopa)
 - e. Sublingual Immunotherapy for Allergies
 - i. Oralair[®]
 - ii. Grastek[®]
 - iii. Ragwitek[™]
 - f. Striverdi[®] Respimat[®] (olodaterol)
 - g. Triumeq[®] (abacavir, dolutegravir, lamivudine)
 - h. Zydelig[®] (idelalisib)
4. Service Authorizations
5. Reports
 - a. ProDUR
 - b. RetroDUR
 - c. Utilization Analysis
 - d. Top Diagnoses by Age
 - e. AAP Report
6. Future Topics
 - a. Metabolic Monitoring in Patients on Atypical Antipsychotics – *in process*
 - b. Analysis of Compounded Medications to review ingredients
7. Other Business
8. Adjournment